Combination may offer a substitute to basal-bolus insulin in people with type 2 diabetes inadequately controlled with daily basal insulin.

Today, patients on insulin receive injections daily, or even more often, but both companies are working to change that.

Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...

The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...

The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...

Novo Nordisk already has regulatory approvals for its once-weekly insulin, icodec. In Europe, Canada, Australia, Japan, and Switzerland, this product is marketed as Awiqli for the treatment of ...

For people with type 1 diabetes, management burden including suboptimal insulin preparations remains a major barrier to ...

If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.

Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...

Insulin efsitora was able to lower A1C in patients with type 1 diabetes but more patients experienced severe hypoglycemic ...

Medscape Medical News, March 27, 2024 Novo Nordisk's Once-weekly Basal Insulin Icodec Recommended for Marketing Approval in Europe Danish drugmaker Novo Nordisk on Thursday said its once-weekly ...

Two studies presented at a major diabetes conference suggest patients could swap daily insulin injections for a weekly dose.